A new Center for Computational Immunology at New York City-based Mount Sinai's Icahn School of Medicine will serve as a research hub for the study and discovery of targeted immunotherapies for cancer patients.
The center aims to increase the number of patients who benefit from cancer-killing immunotherapy drugs. To do so, researchers will utilize genomics, machine learning and immunology, and "look further into the tumor microenvironment for answers," according to Miriam Merad, MD, PhD, director of Mount Sinai's Precision Immunology Institute.
"We want to understand how to model interactions between cancers and the immune system to help more people benefit from the life-saving potential of immunotherapy," Benjamin Greenbaum, PhD, an assistant professor at Mount Sinai and director of the hub, said in a statement.
The center officially launched on May 9 and is a collaboration between the Precision Immunology Institute and the Tisch Cancer Institute.
More articles about health IT:
US indicts Chinese hacker for exposing 80M Anthem patient records
Harvard Business Review: Look at AI as a system-wide update, not a point solution
Genetic mutation linked to higher fatality rate in prostate cancer patients